Candlestick · Volume · EMA · BB · VWAP · MACD · RSI · Drawing Tools
Candlestick chart with volume — data via Yahoo Finance · For educational use only
Regeneron Pharmaceuticals (REGN) is back in focus after Japan approved Dupixent as the first targeted treatment for adults with moderate to severe bullous pemphigoid, expanding the drug’s reach in a rare skin disease. See our latest analysis for Regeneron Pharmaceuticals. The Dupixent approval in Japan has arrived while Regeneron’s 1 day share price return of 1.57% and 7 day share price return of 1.73% contrast with a 30 day share price decline of 4.14%, and a 1 year total shareholder return...
Bayer Wins EC Approval to Expand Kerendia in Heart Failure Treatment
Bayer wins EU nod to expand Kerendia's use in heart failure, backed by strong phase III data, boosting a key drug driving growth and portfolio momentum.
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
ANIP Stock Outlook: Cortrophin Growth vs. Retina Reset
ANI Pharmaceuticals' growth pivots to Cortrophin Gel as retina headwinds weigh on 2025, with 2026 recovery hopes hinging on specialty momentum and portfolio reset.
Is ANIP Undervalued? How to Read Its 9.3x Forward P/E
ANI Pharmaceuticals trades at just 9.3x forward earnings, far below peers - raising a key question: is this a bargain or a signal of execution risks ahead?
Sentiment scored by an AI model on article tone. Not investment advice.
Trade risk-free with $10,000 virtual cash.
Paper trading only — no real money involved
Open a real trading account with a regulated broker:
View Broker Options →Regeneron (REGN) is currently trading at live market price. See the live chart on this page for the latest move. Prices update live throughout market hours on this page.
Wall Street analyst consensus, AI signals, and recent news sentiment for REGN are shown above. StockifyX surfaces the data; the decision is yours — try the call risk-free with paper trading first.
The next REGN earnings date is shown in the Earnings section above, along with the historical EPS surprise track record.
Dividend yield, payout ratio, and ex-dividend date for REGN are listed in the Dividends card on this page when applicable.
StockifyX gives you $10,000 in virtual cash to paper-trade REGN at real market prices — no real money required. Click "Paper Trade" above to get started.
The latest REGN headlines with sentiment scoring, plus the full Wall Street analyst rating breakdown, are listed further down this page.